Inflation eases to 26-month low in Jan
India's headline inflation slowed to its lowest level in more than two years in January as food prices fell, increasing the pressure on the RBI to cut rates to battle the country's economic slowdown. Full Article
Reuters Showcase
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Ranbaxy gets FDA nod for Glycopyrrolate
U.S.'s next top dog
Two thousand dogs vie to be named "Best in Show" at New York's Westminster Kennel Club Dog Show. Slideshow
MUMBAI |
MUMBAI (Reuters) - Ranbaxy Laboratories, India's top drugmaker by sales, said on Monday it had final approval from the U.S. Food and Drug Administration to make and market peptic ulcer treatment tablet Glycopyrrolate in two variants.
The tablet is the generic version of Sciele Pharma's Robinul and has annual market sales of $26 million, the Indian firm said in a statement.
Ranbaxy, majority owned by Japan's Daiichi Sankyo, plans to launch the tablet in the December quarter.
(For more news on Reuters Money click in.reuters.com/money)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters